Who Should Monitor Biometric Correlation Risk, and How

Building the Monitoring Function That Doesn't Exist Yet

Most reinsurers have a clear owner for mortality assumption monitoring. Almost none have a clear owner for biometric correlation monitoring, because the function has never been explicitly defined.

The strategic case for why this matters sits with the Chief Actuary, covered in what the Chief Actuary should challenge about biometric risk correlation after population events. This post is about the operating model, who runs the monitoring day to day, what data it actually needs, and what should trigger an escalation.

Who Should Own Ongoing Monitoring of This Risk?

A joint function combining actuarial correlation analysis with data science oversight of the biometric data pipeline, reporting into the same governance process used for other assumption risks.

Neither function can do this alone. Actuarial expertise is needed to interpret whether observed co-movement in biometric signals is statistically meaningful or just noise.

Data science expertise is needed to manage the underlying biometric data pipeline well enough to produce reliable cohort-level aggregates in the first place. Splitting ownership between two functions that do not talk to each other regularly is a common way this kind of monitoring quietly fails before it starts.

How Is This Different From Traditional Mortality Monitoring?

Traditional monitoring tracks whether one metric deviates from assumption, while correlation monitoring tracks whether multiple policyholders' signals are moving together, which requires cohort-level analysis.

Actual-to-expected mortality tracking is a single-metric exercise, comparing one number against another over time. Correlation monitoring is structurally different, it requires looking at many individual data series at once and asking whether they are moving in a coordinated way.

That is a harder analytical problem, and it requires data organized differently. Individual-level records are not enough on their own, the monitoring function needs the ability to group and compare those records across defined cohorts.

Why Does Cohort Definition Matter So Much Here?

Because correlation can exist within one cohort definition and be invisible within another.

A correlation that shows up clearly when policyholders are grouped by geography might be invisible when grouped by age band alone, and vice versa. The monitoring function needs to test multiple cohort definitions, not just one default grouping, or it risks missing a real correlation signal simply because it grouped the data the wrong way.

What Data Does Correlation Monitoring Actually Require?

Aggregated, cohort-level biometric signal data over time, not just individual policyholder scores.

Most underwriting data pipelines are built to produce and store an individual risk score, not a time series of the underlying signal that can later be aggregated across a cohort. That is a real infrastructure gap for most reinsurers attempting this kind of monitoring for the first time.

Closing it usually means retaining more granular, time-stamped biometric signal data than has traditionally been kept, specifically so it can be aggregated and compared across cohorts after the fact.

What Should Trigger an Escalation Under This Model?

A statistically significant co-movement in biometric signals across a defined cohort that coincides with, or follows, an identifiable population-level event.

The event component matters, coincidence alone across a small cohort could be noise. A correlation that lines up with a known or emerging population-level shock, a public health event, an economic shock, a climate event, is a much stronger signal that the exposure this whole framework is designed to catch is actually materializing.

Setting this trigger clearly in advance, rather than deciding in the moment whether something looks concerning, is what keeps the escalation process consistent and fast when it actually matters.

How Often Should Correlation Monitoring Run?

Continuously in the background, with formal reporting on a quarterly cycle, and immediate escalation triggered by a detected correlation spike.

Continuous background monitoring means the underlying data pipeline is always being checked, even when nothing unusual is happening. Quarterly formal reporting gives the actuarial and executive functions a routine checkpoint, similar to other standing risk metrics.

The immediate escalation path exists precisely so a real signal does not sit waiting for the next quarterly report to surface, which could mean a meaningful delay during exactly the period the exposure is developing.

Does This Require New Data Infrastructure?

In most cases yes, since correlation monitoring needs cohort-level aggregation capability that individual-level underwriting pipelines are not typically built to produce.

This is not a small technical add-on for most organizations, it is closer to a new capability. Tools like a Behavioral Biometrics Risk AI Agent already process biometric signal data at the individual level, and extending that same data pipeline to support cohort-level aggregation is a more efficient path than building an entirely separate system.

Reinsurers that already have some biometric data infrastructure in place have a real head start here, since the hardest part of this build is usually the data pipeline, not the correlation analysis itself.

How Should This Escalation Model Connect to Executive Reporting?

A confirmed correlation escalation should feed directly into the same reporting channel used for other material assumption risks, not sit isolated inside a data science or actuarial team.

An escalation that stops at the team level that detected it has limited value. The whole point of building this monitoring function is to give executives and the board visibility into a risk they currently cannot see at all, which means the escalation path needs to connect all the way up, not just up to the next manager.

This connects directly to the board-level scenario planning described in how much balance-sheet exposure biometric risk correlation after population events creates, where this same monitoring data becomes the input for a standing board conversation.

What Is a Reasonable First Version of This Capability?

A quarterly cohort-level correlation report covering the largest biometric-informed treaties, expanded over time as the underlying data infrastructure matures.

Building the full version of this monitoring function all at once is unrealistic for most organizations. Starting with the treaties that carry the most biometric-informed pricing concentration gives the highest-value coverage first, while the broader infrastructure and process mature around it.

What Skills Gap Might This Reveal on the Team?

Most actuarial and data teams are strong on individual-level mortality modeling but have limited hands-on experience with cohort-level correlation analysis outside of catastrophe and pandemic modeling.

That gap is worth naming directly rather than discovering informally partway through a project. Correlation analysis of this kind draws on statistical techniques, like copula modeling and cohort clustering, that are more commonly found in catastrophe risk teams than in traditional mortality and morbidity actuarial teams.

The most efficient path for most organizations is not hiring an entirely new team, it is connecting the existing catastrophe or pandemic risk modeling function with the team managing biometric underwriting data, since the correlation techniques already exist inside most reinsurers, just applied to a different risk category.

How Should This Integrate With Existing Catastrophe Risk Modeling Teams?

Biometric correlation monitoring should be built as an extension of existing catastrophe and pandemic risk modeling capability, not as a standalone function competing for separate budget and headcount.

Catastrophe modeling teams already have the statistical toolkit, the organizational mandate, and often the existing relationship with the actuarial function needed to take this on. What they typically lack is access to the underlying biometric data pipeline, which sits with the underwriting or data science function instead.

Formally connecting these two groups, rather than building a third, separate function from scratch, is usually the fastest and most cost-effective way to stand up real correlation monitoring capability. It also avoids the common failure mode of a small, isolated team building a correlation model that never gets proper actuarial or data-governance scrutiny because it exists outside the established structures that would normally provide that oversight.

What Documentation Should This Monitoring Function Produce?

The monitoring function should produce a standing correlation log, a quarterly summary report, and a documented escalation record for any triggered event, kept as a permanent part of the actuarial assumption file rather than informal working notes.

The correlation log should track cohort-level co-movement metrics over time, even in periods where nothing unusual is detected, since a documented history of normal conditions is exactly what makes a future anomaly easier to recognize and defend as genuinely unusual. The quarterly summary translates that log into a format executives and the board can actually use, consistent with the reporting cadence described earlier in this post.

The escalation record matters most during any future review, whether internal, regulatory, or from a rating agency, since it demonstrates the monitoring function was not just built but actually used, with a clear record of what was found and what action followed. Treating this documentation as a permanent, auditable record, rather than disposable working material, is what turns the monitoring function from a one-time initiative into a durable part of the organization's actuarial governance.

That incremental approach also produces something concrete to show executives quickly, a real report with real cohort-level findings, rather than a long infrastructure project with no visible output until it is fully complete. Getting something imperfect but real into executive hands early is usually more valuable than waiting for a complete system that takes years to build.

Sources

• Munich Re: Physical activity measured by wearable sensors can effectively assess mortality risk
• RGA: Managing Pandemic Risk After COVID-19: Lessons from the past, preparing for the future